Healthcare Leaders Hub

🏠Home 📰News 📝Blog 🎬Videos Advertise Login

Your trusted source for pharmaceutical news, expert insights, and healthcare innovation.

💼𝕏 👥▶️

Content

📰News
📝Blog
🎬Videos

Company

🏠Home
🏢About Us
📧Contact

© 2026 PharmaVoice. All rights reserved. Empowering healthcare leaders.

Privacy Policy•Terms of Service

FDA grants RMAT designation to RiboX’s RXRG001 for xerostomia | PharmaVoice

Pharma Tech

FDA grants RMAT designation to RiboX’s RXRG001 for xerostomia

Sep 9, 2026, 8:49 AM

Read Full Article → FDA grants RMAT designation to RiboX’s RXRG001 for xerostomia

FDA grants RMAT designation to RiboX’s RXRG001 for xerostomia

Translate article text

Choose a language and wait for the translated text.

The FDA has granted RMAT designation to RiboX Therapeutics’ investigational treatment RXRG001 for RIX and hyposalivation.